NCT03925285 (SNIPER) is a Phase 1 clinical trial of Bevacizumab-800CW in Inverted Papilloma, sponsored by University Medical Center Groningen.

Who is sponsoring NCT03925285?

NCT03925285 is sponsored by University Medical Center Groningen.

What drugs are being tested in NCT03925285?

Interventions in NCT03925285: Bevacizumab-800CW.

What condition does NCT03925285 study?

NCT03925285 studies Inverted Papilloma, Molecular Fluorescence Imaging.

Is NCT03925285 still recruiting?

NCT03925285 is currently status unknown. Last updated 3 May 2021.

Last reviewed 2021-05-03 · How we verify

NCT03925285: SNIPER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Image Guided Surgery in Sinonasal Inverted Papilloma

Status unknown Phase 1 Last updated 3 May 2021

What this trial tests

Phase 1 trial testing Bevacizumab-800CW in Inverted Papilloma in 6 participants. Status unknown.

Timeline

6 May 2019

Primary endpoint
1 July 2021

1 January 2022

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	6
Start date	6 May 2019
Primary completion	1 July 2021
Estimated completion	1 January 2022
Sites	1 location across Netherlands

Drugs / interventions tested

Bevacizumab-800CW — full drug profile →

Conditions studied

Inverted Papilloma — all drugs for Inverted Papilloma →
Molecular Fluorescence Imaging — all drugs for Molecular Fluorescence Imaging →

Sponsor

University Medical Center Groningen

Who can join

18 and older, any sex, with Inverted Papilloma or Molecular Fluorescence Imaging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In sinonasal inverted papilloma (SNIP) it is very challenging to discriminate between tumor and surrounding tissue. Local recurrence is a frequent phenomenon as it occurs in 16.5% of the cases. There is need for an instrument that is able to guide the surgeon in removing all tumor tissue, whereas resection of healthy tissue is minimalized. Molecular fluorescence guided surgery enables the visualization of targeted tumor-specific biomarkers by using fluorescence, thereby enhancing the contrast between normal mucosa and tumor tissue. The objective of this feasibility study is to determine if the intravenously administered conjugate bevacizumab-IRDye800CW accumulates more in SNIP than in normal sinonasal epithelium.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.
Barth CW, Gibbs SL. · · 2020 · cited 79× · PMID 32255887 · DOI 10.1117/12.2545292
Image-guided surgery and novel intraoperative devices for enhanced visualisation in general and paediatric surgery: a review.
Privitera L, Paraboschi I, Dixit D, Arthurs OJ, et al · · 2021 · cited 20× · PMID 35937852 · DOI 10.1515/iss-2021-0028
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
Giuliani S, Paraboschi I, McNair A, Smith M, et al · · 2024 · cited 14× · PMID 38473402 · DOI 10.3390/cancers16051045
Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial.
Vergeer RA, Postma MR, Schmidt I, Korsten-Meijer AG, et al · · 2021 · cited 6× · PMID 34620658 · DOI 10.1136/bmjopen-2021-049109
Fluorescence grid analysis for the evaluation of piecemeal surgery in sinonasal inverted papilloma: a proof-of-concept study.
Vonk J, Voskuil FJ, de Wit JG, Heeman WT, et al · · 2022 · cited 3× · PMID 34738141 · DOI 10.1007/s00259-021-05567-x

Verify or expand the search:

Other trials of Bevacizumab-800CW

Trials testing the same drug.

NCT06008522 — Safety and Feasibility of Immuno-OCT · NA · unknown
NCT02743975 — Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma · Phase 1, PHASE2 · terminated

Other University Medical Center Groningen trials

Trials by the same sponsor.

NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03925285 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 3 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing